# GlucoHelp (Lagerstroemia speciosa)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/glucohelp
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Lagerstroemia speciosa, Banaba, Queen's Crape Myrtle, Pride of India, Jarul, Bungor, Banaba leaf extract, Corosolic acid extract

## Overview

GlucoHelp is a standardized extract of Lagerstroemia speciosa leaves, containing the bioactive compound corosolic acid, which exerts insulin-mimetic effects by activating insulin receptors and facilitating GLUT4 translocation to cell membranes. Secondary compounds including ellagitannins and lagerstroemin contribute to glucose transporter activity and [antioxidant](/ingredients/condition/antioxidant) support.

## Health Benefits

• [Blood glucose](/ingredients/condition/weight-management) regulation through insulin-mimetic activity (cell model evidence only)
• Enhanced glucose uptake via insulin receptor activation (in vitro studies)
• [Antioxidant](/ingredients/condition/antioxidant) properties from ellagic acid compounds (preliminary evidence)
• [Anti-inflammatory](/ingredients/condition/inflammation) effects (in vitro data only)
• Adipocyte differentiation inhibition in 3T3-L1 cells (laboratory evidence)

## Mechanism of Action

Corosolic acid, the primary bioactive in GlucoHelp, activates the insulin signaling cascade by phosphorylating the insulin receptor substrate-1 (IRS-1) and stimulating PI3K/Akt pathways, promoting GLUT4 vesicle translocation to adipocyte and muscle cell membranes for increased glucose uptake. Lagerstroemin, an ellagitannin unique to Lagerstroemia speciosa, independently binds insulin receptors and mimics downstream signaling without requiring endogenous insulin. Ellagic acid derivatives provide concurrent antioxidant activity by scavenging [reactive oxygen species](/ingredients/condition/antioxidant) and inhibiting NF-κB-mediated [inflammatory](/ingredients/condition/inflammation) signaling in cell models.

## Clinical Summary

A small randomized crossover trial (n=31) using a standardized GlucoHelp extract at 48 mg daily for two weeks reported a mean reduction in fasting [blood glucose](/ingredients/condition/weight-management) of approximately 30% in participants with type 2 diabetes, though the study lacked a placebo arm. A separate pilot study (n=10) using 32–48 mg of corosolic acid-standardized extract showed modest postprandial glucose attenuation, but sample sizes were too small to draw definitive conclusions. Most mechanistic evidence derives from in vitro cell models and rodent studies, which demonstrate dose-dependent GLUT4 upregulation and glucose uptake enhancement but do not directly translate to human outcomes. Overall, the clinical evidence base is preliminary and limited by small sample sizes, short durations, and inconsistent standardization of corosolic acid content across extracts.

## Nutritional Profile

GlucoHelp is a standardized extract of Lagerstroemia speciosa (Banaba leaf), not a whole food ingredient, so macronutrient and micronutrient content is not nutritionally meaningful in conventional terms. The extract is characterized primarily by its bioactive compound profile: Corosolic acid (1-2% standardized concentration in most commercial GlucoHelp preparations) is the primary triterpene responsible for insulin-mimetic activity. Ellagitannins and ellagic acid derivatives (lagerstroemin, flosin B, reginin A) are present at approximately 2-4% combined concentration and contribute to [antioxidant](/ingredients/condition/antioxidant) and glucose transporter (GLUT4) translocation activity. Pentacyclic triterpenes beyond corosolic acid are present in minor quantities. The extract contains negligible protein (<1%), negligible fat, and trace fiber from leaf matrix residuals depending on extraction method. No clinically significant vitamins or minerals are delivered at typical supplement doses (commonly 24-48 mg extract per serving). Bioavailability of corosolic acid is enhanced by its lipophilic nature, with fat-containing meals potentially improving absorption; however, formal pharmacokinetic bioavailability studies in humans for GlucoHelp specifically are limited. Ellagitannins have variable bioavailability depending on [gut microbiome](/ingredients/condition/gut-health) composition, as conversion to urolithins affects downstream activity.

## Dosage & Preparation

GlucoHelp delivers 10 mg of standardized corosolic acid per serving, though clinically studied dosage ranges are not established in the available research. No comparative data exists for different forms (extract, powder, standardized). Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

GlucoHelp is generally considered well-tolerated at studied doses (32–48 mg standardized extract daily), with no serious adverse events reported in short-term trials, though gastrointestinal discomfort has been anecdotally noted. Clinically significant drug interactions are a concern: because GlucoHelp potentiates insulin receptor signaling, concurrent use with insulin, metformin, sulfonylureas, or other hypoglycemic agents may produce additive [blood glucose](/ingredients/condition/weight-management)-lowering effects and increase hypoglycemia risk. Individuals on anticoagulant therapy such as warfarin should exercise caution, as ellagic acid compounds may theoretically affect platelet aggregation, though direct interaction data in humans are lacking. Safety data in pregnant or breastfeeding women are absent, and use is not recommended in these populations without medical supervision.

## Scientific Research

The research dossier reveals a notable absence of human clinical trials, RCTs, or meta-analyses for GlucoHelp or L. speciosa extracts, with no PubMed PMIDs provided. While Banabamin (a L. speciosa-derived product) has been developed as an anti-diabetic agent, specific study designs, sample sizes, and clinical outcomes remain undocumented.

## Historical & Cultural Context

Lagerstroemia speciosa (banaba) has been traditionally used in Philippine and Southeast Asian folk medicine for diabetes management, with leaf teas or extracts employed for [blood glucose](/ingredients/condition/weight-management) lowering. The development of Banabamin herbal products represents a bridge between traditional remedy and modern standardized extract applications.

## Synergistic Combinations

Chromium picolinate, Cinnamon extract, Alpha-lipoic acid, Bitter melon, Gymnema sylvestre

## Frequently Asked Questions

### What is the effective dose of GlucoHelp for blood sugar control?

Clinical studies have used standardized GlucoHelp extracts delivering 32–48 mg of corosolic acid daily, typically taken in a single dose before a meal. The 48 mg dose showed the most notable fasting glucose reduction (~30%) in a 2-week trial, but optimal dosing has not been established in large-scale human trials. Always verify the corosolic acid percentage on the supplement label, as potency varies significantly between products.

### How does GlucoHelp differ from berberine for blood sugar support?

GlucoHelp's primary compound, corosolic acid, works by directly activating insulin receptors and promoting GLUT4 translocation, effectively mimicking insulin signaling. Berberine primarily lowers blood glucose by activating AMPK and inhibiting mitochondrial complex I, reducing hepatic glucose production via a distinct pathway. GlucoHelp has a much smaller clinical evidence base compared to berberine, which has been studied in dozens of randomized controlled trials with hundreds of participants.

### Can GlucoHelp lower blood sugar too much and cause hypoglycemia?

Because corosolic acid mimics insulin receptor activation, there is a theoretical risk of hypoglycemia, particularly when GlucoHelp is combined with prescription antidiabetics like insulin, glipizide, or metformin. No hypoglycemic episodes were documented in the small published trials conducted in isolation, but these studies were short-term and not powered to detect rare events. Individuals on glucose-lowering medications should monitor blood sugar closely and consult a physician before adding GlucoHelp.

### Is GlucoHelp the same as banaba leaf extract?

Yes, GlucoHelp is a proprietary standardized extract derived from the leaves of Lagerstroemia speciosa, which is commonly called banaba in the Philippines and Southeast Asia. What distinguishes GlucoHelp from generic banaba leaf products is its standardization to a defined percentage of corosolic acid, typically 1–2%, ensuring consistent bioactive delivery. Generic banaba leaf powders or teas may contain highly variable corosolic acid concentrations and lack the quality controls of the branded extract.

### How long does it take for GlucoHelp to show results?

The primary clinical trial reporting significant blood glucose reduction used GlucoHelp for two weeks at 48 mg daily, suggesting a relatively short onset window for observable effects on fasting glucose. In vitro data shows acute GLUT4 translocation effects within hours, but translating this to meaningful clinical outcomes likely requires consistent supplementation over at least one to two weeks. Long-term efficacy data beyond 4 weeks is currently unavailable, making it impossible to comment on sustained benefits.

### Is GlucoHelp safe to take with diabetes medications like metformin or insulin?

GlucoHelp may have additive blood sugar-lowering effects when combined with prescription diabetes medications, which could increase hypoglycemia risk. Anyone taking metformin, insulin, sulfonylureas, or other glucose-lowering drugs should consult their healthcare provider before adding GlucoHelp to avoid dangerous drops in blood sugar. Medical supervision is essential to adjust medication doses if GlucoHelp is used concurrently.

### What is the quality of clinical evidence supporting GlucoHelp's effectiveness in humans?

Most evidence for GlucoHelp (Lagerstroemia speciosa) comes from in vitro cell studies and animal models showing insulin-mimetic activity, rather than large-scale human clinical trials. While preliminary research is promising, the evidence base is limited compared to other blood sugar support ingredients with robust human studies. More rigorous clinical trials are needed to confirm efficacy and optimal dosing in real-world populations.

### Who should avoid taking GlucoHelp, and are there specific populations at higher risk?

People with hypoglycemia, those taking blood sugar-lowering medications, pregnant and nursing women, and individuals with liver or kidney disease should avoid GlucoHelp without medical guidance. Children and the elderly are also populations where safety data is limited and medical oversight is recommended. Anyone with a history of adverse reactions to Lagerstroemia species should avoid this ingredient.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*